Numerous recent reports focusing on BRAF-targeted therapy designed to interrupt the RAF/MEK/ERK mitogen activated protein kinase (MAPK) pathway in melanoma patients have not made any distinctions between ERK1 and ERK2 [8-15]. This evidence concerns the gene MAP2K7 and melanoma.